Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA requests 23% increase in funds for FY 2011 - update

This article was originally published in RAJ Devices

Executive Summary

President Barack Obama has requested over $4 billion in funds for the US Food and Drug Administration’s fiscal year 2011 budget1,2. The request represents a 23% increase over the FY 2010 budget, when the FDA received around $3.28 billion3. The money would be used to fund major initiatives aimed at improving medical product safety, protecting patients and modernising the FDA’s regulatory science, among other things.

You may also be interested in...



Global Medtech Guidance Tracker: May 2020

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-one guidance documents have been posted on the tracker since its last update.

Pharma Snubs WHO Call To Pool COVID-19 Patents

Almost three dozen countries have shown support for the alternative mechanism put forward by the World Health Organization to ensure that IP issues do not stand in the way of providing access to COVID-19 medicines, vaccines and diagnostics to ‘all of humanity.’

EMA Creates Internal Repository To Support Regulatory Consistency

Regulatory and scientific discussions undertaken by the European Medicines Agency’s human medicines evaluation committee are finding their way into a new internal repository.

UsernamePublicRestriction

Register

AG002833

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel